Blood Journals Portfolio

New issue of Blood out now featuring Epigenetically activating T cells to attack AML, Ex vivo expansion of human long-term HSCs, and more. Explore here: ashpublications.org/blood/issue/14…

Changes in muscle and fat distribution occur early in treatment highlighting the need for interventions to stabilize body composition. Patients with a higher volume of disease are more likely to experience certain side effects such as nerve pain. ow.ly/JWeb5104eB5

Patient-reported geriatric impairments are common in older adults with MM, including transplant-eligible patients. Older age, comorbidities, patient-reported limitations, and anxiety are significantly associated with high-grade nonhematologic toxicity. ow.ly/RPru5101vMg

A VigiBase analysis identified 19 antineoplastic therapies associated with #VTE risk including a novel link with nintedanib. VTE typically occurs within 6 months of treatment emphasizing the need to include specific therapies in cancer VTE risk assessment. ow.ly/GVNU5103NFN

An 8-gene–based (CHEK1, EXO1, MCM4, TK1, KIF14, SEPTIN11, PHF19 and HMGB3) proliferation score was derived for patients with MM. High proliferation score emerged as an independent prognostic marker. Read in Blood Neoplasia: ow.ly/tseU5103NMG #MultipleMyeloma #BloodNeoplasia